| Print Version (PDF) |
| DAY 1: Wednesday, April 21, 2010 |
| 7:00 – 7:50 a.m. |
Registration |
| 7:50 – 8:15 a.m. |
Opening Remarks and Objectives
Dr. Star and Dr. Kimmel |
| 8:15 – 9:00 a.m. |
Overview/Introduction (30 minutes, followed by 15 minutes of discussion)
Moderator: Dr. Korzenik
- Cytokine Milieu and Outcomes in ESRD Hemodialysis Patients – Dr. Stenvinkel
|
| 9:00 – 10:00 a.m. |
Progress in Cytokine Therapeutics (20 minutes, followed by 10 minutes of discussion)
Moderator: Dr. Carter
- Lessons for Nephrologists From Lupus – Dr. Aringer
- Lessons for Nephrologists From Treatment of Inflammatory Bowel Disease – Dr. Korzenick
|
| 10:00 – 10:30 a.m. |
BREAK |
| 10:30 – 12:00 p.m. |
Progress in Cytokine Therapeutics (20 minutes, followed by 10 minutes of discussion)
Moderator: Dr. Lipsky
- Lessons for Nephrologists From Treatment of Rheumatoid Arthritis – Challenges, Successes, and Combination Therapies – Dr. Weinblatt
- Lessons for Nephrologists From Treatment of Psoriasis – Dr. Gottlieb
- Non-Cytokine Anti-Inflammatory Therapeutics for ESRD Dialysis Patients – Targets and Armamentarium – Dr. Ikizler
|
| 12:00 – 1:00 p.m. |
LUNCH |
| 1:00 – 2:30 p.m. |
Plenary Session (30 minutes, followed by 15 minutes of discussion)
Moderator: Dr. Chertow
- Anti-Cytokine Therapies — What Works and What Doesn’t – and Why – Dr. Oppenheim
- Lessons for Nephrologists From Treatment of ESRD Patients – Challenges, Successes, Adverse Events, and Clinical Trials Tips – Dr. Kaysen
|
| 2:30 – 3:30 p.m. |
Progress and Perils in Cytokine Therapeutics (20 minutes, followed by 10 minutes of discussion)
Moderator: Dr. Gottlieb
- Lessons for Nephrologists from Treatment of a Genetic Disorder – Challenge and Success – Dr. Goldbach-Mansky
- FDA Viewpoints – Adverse Effects of Anti-Cytokine Therapies – Cancer, Infection, and Others – Dr. Siegel
|
| 3:30 – 4:00 p.m. |
BREAK |
| 4:00 – 4:30 p.m. |
Challenges in Clinical Trials in the ESRD Patient (20 minutes, followed by 10 minutes of discussion)
Moderator: Dr. Weinblatt
- Pilot and Feasibility Issues, Power Analyses, Adverse Effects, Biomarkers, Endpoints – Dr. Chertow
|
| 4:30 – 6:30 p.m. |
Breakout Sessions – Charge
Dr. Kimmel
Group Discussion:
- Adverse Events / Pilot and Feasibility Issues – Dr. Cheung
- Combination Therapies and Biologic Issues – Dr. Himmelfarb
- Patient Selection — Inclusion/Exclusion Criteria – Dr. Kaskel
- Biomarkers/Surrogate Markers – Dr. Liu
|
| 6:30 p.m. |
ADJOURN |
| |
|
| DAY 2: Thursday, April 22, 2010 |
| 7:00 – 8:00 a.m. |
Registration |
| 8:00 – 8:30 a.m. |
Plenary Session (20 minutes, followed by 10 minutes of discussion)
Moderator: Dr. Stenvinkel
- Lessons for Nephrologists From Treatment of Diabetes Mellitus – Dr. Donath
|
| 8:30 – 9:30 a.m. |
Presentation (20 minutes, followed by 10 minutes of discussion)
Moderator: Dr. Kimmel
- Public – Private Partnerships/Collaborative Opportunities/An NIH View – Dr. Mayrand-Chung
- Intellectual Property – An NIDDK View – Ms. Lake
|
| 9:30 – 11:30 a.m. |
Industry Round Table
- Abbott – Dr. Andress
- Amgen – Dr. Pollock
- Celgene – Dr. Stevens
- J and J / Centocor – Dr. Chevrier
- Novartis – Dr. Lorber
- Regeneron – Dr. Mellis
- Roche / Genetech – Dr. Lee
- UCB – Dr. Chartash
|
| 11:30 – 12:00 p.m. |
BREAK |
| 12:00 – 2:00 p.m. |
WORKING LUNCH - BREAKOUT GROUPS |
| 2:00 – 3:00 p.m. |
Reports from the Breakout Sessions |
| 3:00 – 4:00 p.m. |
Open Discussion |
| 4:00 p.m. |
ADJOURN |
| |
|
| |
|
